RAPAGEN Trademark

Trademark Overview

On Thursday, September 6, 2018, a trademark application was filed for RAPAGEN with the United States Patent and Trademark Office. The USPTO has given the RAPAGEN trademark a serial number of 88106867. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, May 16, 2022. This trademark is owned by Vascular Therapies, Inc.. The RAPAGEN trademark is filed in the Pharmaceutical Products category with the following description:

An implantable drug delivery matrix for intraoperative delivery of sirolimus to the vascular wall, the formulation consisting of a collagen membrane incorporating an active pharmaceutical ingredient, namely, sirolimus, for improving functional outcomes of procedures that involve the creation of a vascular anastomosis
rapagen

General Information

Serial Number88106867
Word MarkRAPAGEN
Filing DateThursday, September 6, 2018
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, May 16, 2022
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, February 12, 2019

Trademark Statements

Goods and ServicesAn implantable drug delivery matrix for intraoperative delivery of sirolimus to the vascular wall, the formulation consisting of a collagen membrane incorporating an active pharmaceutical ingredient, namely, sirolimus, for improving functional outcomes of procedures that involve the creation of a vascular anastomosis

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, September 14, 2018
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameVascular Therapies, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressCresskill, NJ 07626
Party NameVascular Therapies, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressCresskill, NJ 07626

Trademark Events

Event DateEvent Description
Monday, May 16, 2022ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, May 16, 2022ABANDONMENT - NO USE STATEMENT FILED
Thursday, September 23, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, September 22, 2021SOU EXTENSION 5 GRANTED
Friday, September 17, 2021SOU EXTENSION 5 FILED
Wednesday, September 22, 2021CASE ASSIGNED TO INTENT TO USE PARALEGAL
Friday, September 17, 2021SOU TEAS EXTENSION RECEIVED
Thursday, April 8, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, April 6, 2021SOU EXTENSION 4 GRANTED
Tuesday, April 6, 2021SOU EXTENSION 4 FILED
Tuesday, April 6, 2021SOU TEAS EXTENSION RECEIVED
Friday, October 2, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, September 30, 2020SOU EXTENSION 3 GRANTED
Wednesday, September 30, 2020SOU EXTENSION 3 FILED
Wednesday, September 30, 2020SOU TEAS EXTENSION RECEIVED
Wednesday, March 25, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, March 23, 2020SOU EXTENSION 2 GRANTED
Monday, March 23, 2020SOU EXTENSION 2 FILED
Monday, March 23, 2020SOU TEAS EXTENSION RECEIVED
Tuesday, September 24, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, September 20, 2019SOU EXTENSION 1 GRANTED
Friday, September 20, 2019SOU EXTENSION 1 FILED
Friday, September 20, 2019SOU TEAS EXTENSION RECEIVED
Tuesday, April 9, 2019NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, February 12, 2019OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, February 12, 2019PUBLISHED FOR OPPOSITION
Wednesday, January 23, 2019NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Monday, January 7, 2019ASSIGNED TO LIE
Wednesday, January 2, 2019TEAS VOLUNTARY AMENDMENT RECEIVED
Friday, December 21, 2018APPROVED FOR PUB - PRINCIPAL REGISTER
Thursday, December 20, 2018EXAMINER'S AMENDMENT ENTERED
Thursday, December 20, 2018NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Thursday, December 20, 2018EXAMINERS AMENDMENT E-MAILED
Thursday, December 20, 2018EXAMINERS AMENDMENT -WRITTEN
Monday, December 17, 2018ASSIGNED TO EXAMINER
Friday, September 14, 2018NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, September 10, 2018NEW APPLICATION ENTERED

Related Keywords

rapagen sirolimus delivery vascular functional improving namely ingredient outcomes procedures involve